Skip Navigation LinksHome > January 2014 - Volume 29 - Issue 1 > Pooled analysis of adjunct extended-release quetiapine fumar...
International Clinical Psychopharmacology:
doi: 10.1097/YIC.0000000000000011
Original Articles

Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment

Bauer, Michaela; Demyttenaere, Koenb; El-Khalili, Nizarc; Thase, Michael E.d; Papakostas, George I.e; Szamosi, Johanf; Earley, Willie R.g; Eriksson, Hansf

Collapse Box

Abstract

This pooled analysis evaluated the efficacy of extended-release quetiapine fumarate (quetiapine XR) adjunct to selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) in patients with major depressive disorder (MDD). Pooled data were analyzed from two 6-week, double-blind, randomized, placebo-controlled trials of adjunct quetiapine XR (150 and 300 mg/day) in patients with MDD and inadequate response to initial antidepressant monotherapy. This post-hoc analysis included evaluation of change from randomization at week 6 in Montgomery Åsberg Depression Rating Scale (MADRS) total scores (primary endpoint), and week 6 MADRS response and remission rates for quetiapine XR as an adjunct to ongoing SSRI or SNRI. In total, 189, 178, and 202 patients received quetiapine XR 150 mg/day+SSRI, 300 mg/day+SSRI, and placebo+SSRI, respectively, whereas 82, 90, and 76 patients, respectively, received quetiapine XR 150 mg/day+SNRI, 300 mg/day+SNRI, and placebo+SNRI. At week 6, quetiapine XR 150 mg/day+SSRI and 300 mg/day+SSRI reduced the MADRS total score from randomization versus placebo+SSRI [least squares mean (LSM) change, −14.70 (P<0.05) −14.72 (P<0.05) vs. –12.59, respectively]. Quetiapine XR 150 mg/day+SNRI (LSM change, –14.68, P<0.01) and 300 mg/day+SNRI (LSM change, –14.99, P<0.01) also reduced the MADRS total score from randomization at week 6 versus placebo+SNRI (−10.77). In conclusion, in patients with MDD and inadequate response to ongoing antidepressant, adjunct quetiapine XR (150 and 300 mg/day) was effective in both SSRI and SNRI subgroups.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.